Haemonetics (NYSE:HAE) has earned an average recommendation of “Hold” from the thirteen ratings firms that are currently covering the stock, Stock Ratings Network.com reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. Haemonetics Corporation (NYSE:HAE) shares after opening at $33.66 moved to $33.66 on last trade day and at the end of the day closed at $31.84. Company price to sales ratio in past twelve months was calculated as 1.74 and price to cash ratio as 9.26. Haemonetics Corporation (NYSE:HAE) showed a negative weekly performance of -15.07%.
Community Health Systems (NYSE:CYH) had its price target trimmed by Mizuho from $44.00 to $38.00 in a research report sent to investors on Wednesday morning, Analyst Ratings Network reports. Community Health Systems (NYSE:CYH) shares advanced 0.20% in last trading session and ended the day on $35.29. CYH return on equity ratio is recorded as 4.80% and its return on assets is 0.80%. Community Health Systems (NYSE:CYH) yearly performance is -22.71%.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Initial public offering of 5,882,353 shares of common stock was set at $17.00 per share. In addition, Akebia has granted the underwriters a 30-day over-allotment option to purchase up to an additional 879,647 shares of common stock at the initial public offering price. Akebia Therapeutics Inc. (NASDAQ:AKBA) shares moved down -0.99% in last trading session and was closed at $20.00, while trading in range of $18.96 – $20.50. Akebia Therapeutics Inc. (NASDAQ:AKBA) year to date (YTD) performance is -25.07%.
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced the closing of its initial public offering of 3,263,010 ordinary shares at a public offering price of $13.50 per share, which included 425,610 ordinary shares issued upon the exercise in full of the underwriters’ option to purchase additional ordinary shares to cover over-allotments. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) weekly performance is -24.34%. On last trading day company shares ended up $11.53. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) distance from 50-day simple moving average (SMA50) is -18.38%.